BIOVF (Swedish Orphan Biovitrum AB) Total Stockholders Equity : $3,852 Mil (As of Mar. 2025)

View and export this data going back to 2010. Start your Free Trial

What is Swedish Orphan Biovitrum AB Total Stockholders Equity?

Swedish Orphan Biovitrum AB's Total Stockholders Equity for the quarter that ended in Mar. 2025 was $3,852 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Swedish Orphan Biovitrum AB's Book Value per Share for the quarter that ended in Mar. 2025 was $11.21. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Swedish Orphan Biovitrum AB's Debt-to-Equity for the quarter that ended in Mar. 2025 was 0.36.

Swedish Orphan Biovitrum AB Total Stockholders Equity Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB Total Stockholders Equity Chart

Swedish Orphan Biovitrum AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

2,416.09

2,552.70

2,555.89

3,301.65

3,667.37

Swedish Orphan Biovitrum AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Stockholders Equity	Get a 7-Day Free Trial															3,446.93	3,464.86	3,626.36	3,667.37	3,851.75

Swedish Orphan Biovitrum AB (OTCPK:BIOVF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Swedish Orphan Biovitrum AB's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(3851.749	-	0)	/	343.457
	=	11.21

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Swedish Orphan Biovitrum AB's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(395.942	+	987.782)	/	3851.749
	=	0.36

Swedish Orphan Biovitrum AB Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Swedish Orphan Biovitrum AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OTCPK:BIOVF) » Definitions » Total Stockholders Equity

Traded in Other Exchanges

SWOBY:USA SOBI:Sweden 1SOBI:Italy SOBIs:UK 0MTD:UK B6E:Germany

Address

Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76

Website

https://www.sobi.com

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).